MET and non-small cell lung carcinoma: It is a phase II, single-arm study evaluating the efficacy of osimertinib in combination with savolitinib in 259 patients with EGFRm and MET amplified and/or c-MET overexpressed locally advanced or metastatic NSCLC who have progressed on osimertinib.